MeSH term
Frequency | Condition_Probility | English Abstract | 37 | 0.0 |
Humans | 134 | 0.0 |
Female | 74 | 0.0 |
Male | 70 | 0.0 |
Middle Aged | 53 | 0.0 |
Amino Acid Sequence | 3 | 0.0 |
Animals | 44 | 0.0 |
Cattle | 2 | 0.0 |
Cells, Cultured | 10 | 0.0 |
Membrane Proteins/metabolism | 3 | 0.0 |
Molecular Sequence Data | 4 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 4 | 0.0 |
Disease Models, Animal | 2 | 0.0 |
Mice | 16 | 0.0 |
Neoplasm Transplantation | 7 | 0.0 |
Peptide Fragments/pharmacology | 2 | 0.0 |
Peptides/genetics/*metabolism | 4 | 12.0 |
Research Support, Non-U.S. Gov't | 49 | 0.0 |
Transfection | 5 | 0.0 |
Transplantation, Heterologous | 4 | 0.0 |
Adult | 49 | 0.0 |
Aged | 34 | 0.0 |
Peptides/administration & dosage/blood/*pharmacology | 2 | 40.0 |
Rats | 16 | 0.0 |
Rats, Wistar | 5 | 0.0 |
*Apoptosis/drug effects | 2 | 1.0 |
Cell Division/drug effects | 7 | 0.0 |
Immunohistochemistry | 12 | 0.0 |
Peptides/genetics/*metabolism/pharmacology | 3 | 50.0 |
RNA, Messenger/genetics/metabolism | 2 | 0.0 |
Receptors, Peptide/genetics/*metabolism | 2 | 18.0 |
Adolescent | 10 | 0.0 |
Child | 7 | 0.0 |
Child, Preschool | 6 | 0.0 |
Peptides/*blood | 17 | 25.0 |
Time Factors | 8 | 0.0 |
Blotting, Northern | 5 | 0.0 |
Dogs | 3 | 0.0 |
Heart Failure, Congestive/blood/*metabolism | 2 | 100.0 |
Hormones/blood | 2 | 1.0 |
In Situ Hybridization | 2 | 0.0 |
Myocardium/*metabolism | 5 | 2.0 |
RNA, Messenger/metabolism | 2 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 15 | 0.0 |
Ventricular Function, Left | 2 | 6.0 |
Drug Screening Assays, Antitumor | 3 | 0.0 |
Tumor Cells, Cultured | 12 | 0.0 |
Cell Survival/drug effects | 4 | 0.0 |
Up-Regulation | 2 | 0.0 |
Analysis of Variance | 4 | 0.0 |
Case-Control Studies | 3 | 0.0 |
Dose-Response Relationship, Drug | 7 | 0.0 |
Vasodilator Agents/pharmacology | 3 | 5.0 |
Comparative Study | 24 | 0.0 |
Dental Plaque Index | 2 | 8.0 |
Follow-Up Studies | 4 | 0.0 |
Gingivoplasty/methods | 2 | 100.0 |
Periodontal Index | 3 | 6.0 |
Single-Blind Method | 2 | 0.0 |
Surgical Flaps | 2 | 11.0 |
Wound Healing | 2 | 1.0 |
Vasodilator Agents/*blood | 2 | 66.0 |
Colonic Neoplasms/*pathology | 2 | 2.0 |
Injections, Intravenous | 4 | 0.0 |
Liposomes | 5 | 1.0 |
Mice, Inbred BALB C | 6 | 0.0 |
Antineoplastic Agents/*therapeutic use | 8 | 2.0 |
Blotting, Western | 4 | 0.0 |
Peptides/*metabolism | 4 | 2.0 |
Tissue Distribution | 6 | 0.0 |
Cyclic AMP/metabolism | 5 | 0.0 |
Cross-Over Studies | 3 | 0.0 |
Double-Blind Method | 2 | 0.0 |
Radioimmunoassay | 4 | 0.0 |
Renin/blood | 4 | 1.0 |
Pregnancy | 4 | 0.0 |
Blood Pressure | 4 | 0.0 |
Reference Values | 3 | 0.0 |
Antineoplastic Agents/pharmacology | 2 | 0.0 |
Gene Expression | 4 | 0.0 |
Immunoenzyme Techniques | 2 | 0.0 |
RNA, Messenger/biosynthesis | 4 | 0.0 |
Hemodynamic Processes | 3 | 1.0 |
Nitrates/blood | 3 | 11.0 |
Nitrites/blood | 3 | 12.0 |
Norepinephrine/blood | 3 | 1.0 |
*Renal Dialysis | 2 | 0.0 |
Skin Transplantation/*methods | 2 | 50.0 |
Statistics, Nonparametric | 3 | 0.0 |
Heart Rate | 2 | 0.0 |
Doxorubicin/pharmacology | 3 | 1.0 |
Drug Resistance, Neoplasm | 3 | 0.0 |
Neoplasm Recurrence, Local | 4 | 0.0 |
Tumor Cells, Cultured/drug effects | 6 | 1.0 |
Breast Neoplasms/*drug therapy | 2 | 3.0 |
Mice, Nude | 9 | 0.0 |
Blood Pressure/drug effects | 4 | 0.0 |
Heart Rate/drug effects | 4 | 1.0 |
Hemodynamic Processes/*drug effects | 3 | 2.0 |
Cardiovascular Physiology | 2 | 10.0 |
Binding, Competitive | 2 | 0.0 |
Calcitonin Gene-Related Peptide/pharmacology | 4 | 13.0 |
Kinetics | 4 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 2 | 0.0 |
Iodine Radioisotopes/diagnostic use | 3 | 0.0 |
Nitric Oxide/metabolism | 4 | 2.0 |
Motor Cortex/*physiology | 2 | 10.0 |
Angiotensin II/*pharmacology | 2 | 1.0 |
Enzyme Inhibitors/pharmacology | 2 | 0.0 |
Forskolin/pharmacology | 2 | 0.0 |
Peptides/*pharmacology | 6 | 2.0 |
Rabbits | 4 | 0.0 |
Receptors, Calcitonin Gene-Related Peptide/metabolism | 2 | 50.0 |
*Receptors, Peptide | 6 | 25.0 |
*Apoptosis | 2 | 0.0 |
Atrial Natriuretic Factor/blood | 2 | 2.0 |
Postoperative Period | 4 | 1.0 |
Aged, 80 and over | 5 | 0.0 |
Chromatography, High Pressure Liquid | 2 | 0.0 |
Drug Combinations | 2 | 0.0 |
Echocardiography | 2 | 0.0 |
Peptides/blood/*pharmacology | 2 | 28.0 |
Vasodilator Agents/*pharmacology | 4 | 8.0 |
Peptides/chemistry/*physiology | 2 | 40.0 |
Rats, Sprague-Dawley | 3 | 0.0 |
Peptide Fragments/*pharmacology | 2 | 1.0 |
Administration, Intravesical | 3 | 11.0 |
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use | 8 | 1.0 |
Doxorubicin/administration & dosage/*therapeutic use | 3 | 75.0 |
Neoplasm Recurrence, Local/*prevention & control | 2 | 14.0 |
Treatment Outcome | 3 | 0.0 |
Anoxia/*metabolism | 2 | 3.0 |
Peptides/*genetics | 2 | 2.0 |
Membrane Proteins/*metabolism | 2 | 0.0 |
Peptides/metabolism/*pharmacology | 2 | 8.0 |
Cisplatin/administration & dosage | 4 | 1.0 |
Cyclophosphamide/administration & dosage | 5 | 2.0 |
Doxorubicin/administration & dosage | 7 | 3.0 |
Vinblastine/administration & dosage | 2 | 4.0 |
*Peptide Biosynthesis | 3 | 10.0 |
*Transcription, Genetic/drug effects | 2 | 1.0 |
Cyclooxygenase Inhibitors/pharmacology | 2 | 2.0 |
Osmolar Concentration | 2 | 0.0 |
Drug Synergism | 2 | 0.0 |
Aminopyrine N-Demethylase/metabolism | 2 | 50.0 |
*Aryl Hydrocarbon Hydroxylases | 2 | 0.0 |
Cytochrome P-450 Enzyme System/*metabolism | 2 | 0.0 |
Isoenzymes/*metabolism | 2 | 0.0 |
Oxidoreductases, N-Demethylating/metabolism | 2 | 3.0 |
In Vitro | 3 | 0.0 |
Nitric-Oxide Synthase/antagonists & inhibitors | 2 | 4.0 |
Cell Line | 7 | 0.0 |
Infusions, Intravenous | 4 | 0.0 |
Peptides/administration & dosage/*pharmacology | 2 | 22.0 |
Fluorouracil/administration & dosage | 4 | 3.0 |
Methotrexate/administration & dosage | 2 | 2.0 |
Prospective Studies | 3 | 0.0 |
Survival Rate | 3 | 0.0 |
Drug Administration Schedule | 5 | 0.0 |
Mitoxantrone/administration & dosage | 2 | 7.0 |
Prednisolone/administration & dosage | 4 | 5.0 |
Vincristine/administration & dosage | 4 | 2.0 |
Doxorubicin/*administration & dosage/pharmacokinetics | 3 | 100.0 |
Drug Carriers | 3 | 2.0 |
Doxorubicin/*administration & dosage/therapeutic use | 2 | 50.0 |
Infusions, Intra-Arterial | 2 | 3.0 |
Antineoplastic Agents/*pharmacology | 7 | 0.0 |
Drug Resistance | 7 | 1.0 |
Proto-Oncogene Proteins c-bcl-2 | 2 | 1.0 |
Lung Neoplasms/*pathology | 2 | 2.0 |
RNA, Messenger/analysis | 2 | 0.0 |
Body Mass Index | 2 | 0.0 |
Chemotherapy, Adjuvant | 3 | 1.0 |
Doxorubicin/administration & dosage/*pharmacokinetics | 2 | 100.0 |
Hepatic Artery | 3 | 5.0 |
Liver/metabolism | 3 | 0.0 |
Etoposide/administration & dosage | 2 | 1.0 |
Drug Therapy, Combination | 4 | 0.0 |
Leukemia, Myeloid/pathology | 2 | 9.0 |
Pancreatic Neoplasms/*pathology | 2 | 5.0 |
Immunotoxins/*therapeutic use | 2 | 4.0 |
Prognosis | 4 | 0.0 |
Drug Evaluation | 2 | 0.0 |
Carcinoembryonic Antigen/analysis | 2 | 1.0 |
Evaluation Studies | 2 | 0.0 |
Mitomycin | 2 | 4.0 |
Random Allocation | 5 | 1.0 |
Leukemia/*pathology | 2 | 4.0 |
Doxorubicin/*pharmacology | 2 | 2.0 |
Adenocarcinoma/pathology | 2 | 2.0 |
Bone Marrow/metabolism | 2 | 1.0 |
Flow Cytometry | 2 | 0.0 |
Verapamil/*pharmacology | 2 | 6.0 |
Antineoplastic Combined Chemotherapy Protocols/therapeutic use | 2 | 0.0 |
Clinical Trials | 2 | 0.0 |
Combined Modality Therapy | 2 | 0.0 |
Nimustine | 3 | 75.0 |
Astrocytoma/drug therapy/therapy | 2 | 100.0 |
*Bone Marrow Transplantation | 2 | 0.0 |
Brain Neoplasms/*drug therapy/radiotherapy/therapy | 2 | 100.0 |
Glioma/*drug therapy/radiotherapy/*therapy | 2 | 100.0 |
Nitrosourea Compounds/therapeutic use | 2 | 50.0 |
Swine | 2 | 0.0 |
Doxorubicin/*therapeutic use | 2 | 8.0 |
